Santarus, Inc. - SNTS - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: June 16, 2013

Santarus, Inc. - SIC # 2834

Ticker	Exchange	SIC #	Website	Latest Ticker
SNTS	Nasdaq	2834	http://www.santarus.com	22.28 +0.76
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Santarus, Inc. ViroPharma Up on Takeover Rumors - Jun 18th, 2013 2:35 pm AstraZeneca and NGM Collaborate - Jun 18th, 2013 2:20 pm Positive Data on Incyte's Jakafi - Jun 18th, 2013 2:00 pm Data on Astex Candidate - Jun 18th, 2013 1:40 pm MannKind Completes Afrezza Studies - Jun 18th, 2013 12:30 pm Santarus says FDA accepts Ruconest application - Jun 18th, 2013 10:15 am Santarus says FDA accepts Ruconest application - Jun 18th, 2013 10:15 am Perrigo in Expansion Mode - Jun 18th, 2013 9:10 am Good News for Celgene's Pipeline - Jun 18th, 2013 8:30 am SANTARUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits - Jun 18th, 2013 7:07 am Santarus and Pharming announce FDA acceptance for review of RUCONEST (recombinant human C1 esterase inhibitor) Biologics License Application - Jun 17th, 2013 11:02 pm Santarus and Pharming Announce FDA Acceptance for Review of RUCONEST (Recombinant Human C1 Esterase Inhibitor) Biologics License Application - Jun 17th, 2013 11:00 pm US Launch of Forest's Namenda XR - Jun 17th, 2013 3:00 pm XOMA Commences Gevokizumab Study - Jun 17th, 2013 12:20 pm Data on BMY/ AbbVie's elotuzumab - Jun 17th, 2013 8:50 am Santarus President & CEO Gerald Proehl Honored as San Diego Ernst & Young Entrepreneur of the Year 2013 in Life Sciences - Jun 17th, 2013 5:30 am New Data on UCB's Cimzia - Jun 14th, 2013 2:35 pm FDA Panel Meeting for Salix Drug - Jun 13th, 2013 2:25 pm Incyte's Jakafi Label Updated - Jun 13th, 2013 12:10 pm Santarus price increases positive, says Roth Capital - Jun 13th, 2013 6:24 am View All Current Headlines >>